Resalis Therapeutics

About Resalis Therapeutics

Resalis Therapeutics is dedicated to developing RNA-based therapies that address the root causes of complex metabolic disorders, with a focus on advancing safe, effective, and disease-modifying treatments for sustained weight loss and improved metabolic health.

Products & Services

RES-010:A non-coding RNA drug candidate designed to treat metabolic diseases, currently in Phase 1 clinical trials, initially targeting obesity and fatty liver disease.

Specialties

Non-coding RNA therapies Lipid metabolism Metabolic disorders Obesity treatment Fatty liver disease treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 11000000 MR: - FA: €10 million FAN: 11000000	D: 2024-01-04 FD: 2024-01-04	3 investors
2	RT: Seed T: - FT: Seed	A: 10720000 MR: - FA: €10 million FAN: 10720000	D: 2023-02-22 FD: 2023-02-22	3 investors

Series A Latest

2024-01-04

$11.0M

3 investors (Pro only)

Seed 2023-02-22

$10.7M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Alessandro Toniolo

Chief Executive Officer

LinkedIn (Pro only)

A

Almut Nitsche

Chief Medical and Development Officer

LinkedIn (Pro only)

R

Riccardo Panella

Chief Scientific Officer & Co-Founder

LinkedIn (Pro only)

S

Sakari Kauppinen

Chief Technology Officer & Co-Founder

T

Thomas Eichinger

Chief Technical Development Officer

M

Maria Vittoria Verga Falzacappa

Publication Lead

View 11 more team members with Pro

Unlock Full Team Directory

Recent News